An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

NCT03363776 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Cancer

Interventions

BIOLOGICAL: BMS-986277
BIOLOGICAL: Nivolumab

Sponsor

Bristol-Myers Squibb